A system for delivering one or more substances into a Fallopian tube of a patient may include a balloon catheter including a tube having a distal end, a balloon having a first end coupled to the distal end of the tube, and a push wire having a distal end coupled to a second end of the balloon, which may be hollow. The balloon may be movable between an inverted position and an everted position. The balloon catheter may be configured to receive the one or more substances such that the one or more substances may be retained by the balloon, or delivered through the push wire, or both. During eversion, or in the everted position, or both, the one or more substances may be delivered into the Fallopian tube.

A system for delivering one or more substances into a Fallopian tube of a patient may include a balloon catheter including a tube having a distal end, a balloon having a first end coupled to the distal end of the tube, and a push wire having a distal end coupled to a second end of the balloon, which may be hollow. The balloon may be movable between an inverted position and an everted position. The balloon catheter may be configured to receive the one or more substances such that the one or more substances may be retained by the balloon, or delivered through the push wire, or both. During eversion, or in the everted position, or both, the one or more substances may be delivered into the Fallopian tube.

Embodiments of the present disclosure relate an ovarian characteristic measurement method and system. A data interface is configured to receive a set of reproductive health data of a patient. The reproductive health data is processed using an ovarian characteristic data structure stored in memory. The data structure is generated from an ovarian characteristic data model that defines the ovarian characteristic. For instance, the data model defines a processing of the reproductive health data to yield a measurement of the ovarian characteristic. Accordingly, a format of the ovarian data structure is selected to optimize computing resources required to process the set of reproductive health data. The method and system then determine a value of the ovarian characteristic of the patient based on the processing of the set of reproductive health data.

Described here are methods and systems for the manipulation of ovarian tissues. The methods and systems may be used in the treatment of polycystic ovary syndrome (PCOS). The systems and methods may also be useful in the treatment of infertility associated with PCOS.

Everting balloon systems and methods for using the same with an alignment element for stability and anti-rotation of the everting balloon are disclosed herein. The systems can be configured to access and deliver instruments, media, or other catheters into bodily lumens and cavities. The alignment element can eliminate the potential for the everting membrane to become twisted or rotated which could impact access or the ability of the system to deliver materials. A compliance member can facilitate internal pressurization of the everting catheter system. An everting catheter system can be configured for use with transvaginal ultrasound and a lower profile speculum is described.

Everting balloon systems and methods for using the same with an alignment element for stability and anti-rotation of the everting balloon are disclosed herein. The systems can be configured to access and deliver instruments, media, or other catheters into bodily lumens and cavities. The alignment element can eliminate the potential for the everting membrane to become twisted or rotated which could impact access or the ability of the system to deliver materials. A compliance member can facilitate internal pressurization of the everting catheter system. An everting catheter system can be configured for use with transvaginal ultrasound and a lower profile speculum is described.

A kit having instructions for use for performing uterine lavage in a female patient includes a uterine lavage catheter configured for insertion into a woman's uterus to remove viable blastocysts from the uterus, and one or more first containers having a sufficient dosage amount of a GnRH antagonist to cause desynchronization of the endometrium of the patient prior to, during and/or following recovery of viable blastocysts from the uterus.

A kit having instructions for use for performing uterine lavage in a female patient includes a uterine lavage catheter configured for insertion into a woman's uterus to remove viable blastocysts from the uterus, and one or more first containers having a sufficient dosage amount of a GnRH antagonist to cause desynchronization of the endometrium of the patient prior to, during and/or following recovery of viable blastocysts from the uterus.

A kit having instructions for use for performing uterine lavage in a female patient includes a uterine lavage catheter configured for insertion into a woman's uterus to remove viable blastocysts from the uterus, and one or more first containers having a sufficient dosage amount of a GnRH antagonist to cause desynchronization of the endometrium of the patient prior to, during and/or following recovery of viable blastocysts from the uterus.

A kit having instructions for use for performing uterine lavage in a female patient includes a uterine lavage catheter configured for insertion into a woman's uterus to remove viable blastocysts from the uterus, and one or more first containers having a sufficient dosage amount of a GnRH antagonist to cause desynchronization of the endometrium of the patient prior to, during and/or following recovery of viable blastocysts from the uterus.